CURRICULUM VITAE
Corey A. Siegel, MD
WORK ADDRESS
Dartmouth-Hitchcock Medical Center
Section of Gastroenterology
One Medical Center Drive
Lebanon, NH 03756
Phone 603-650-8101
E-mail [email protected]
DATE OF BIRTH:
June 15, 1971
PLACE OF BIRTH:
Hackensack, NJ
HOME ADDRESS
5 Carriage Lane
Hanover, NH 03755
603-643-1218
EDUCATION
2007-2009
1994-1998
1989-1993
M.S., Clinical/Health Services Research, The Dartmouth Institute for
Health Policy and Clinical Practice, Dartmouth Medical School, Hanover,
New Hampshire
M.D., Tufts University School of Medicine, Boston, Massachusetts
B.S., Tufts University College of Liberal Arts, Medford, Massachusetts
POSTDOCTORAL TRAINING
2004-2005
2002-2005
2001-2002
1999-2001
1998-1999
Advanced Fellowship in Inflammatory Bowel Disease,
Massachusetts General Hospital, Boston, Massachusetts
Mentors: Dr. Bruce E. Sands & Dr. Joshua R. Korzenik
Fellow in Gastroenterology, Dartmouth-Hitchcock Medical Center,
Lebanon, New Hampshire
Chief Medical Resident, Dartmouth-Hitchcock Medical Center,
Lebanon, New Hampshire
Resident, Internal Medicine, Dartmouth-Hitchcock Medical Center,
Lebanon, New Hampshire
Intern, Internal Medicine, Dartmouth-Hitchcock Medical Center,
Lebanon, New Hampshire
ACADEMIC APPOINTMENTS
2012-present Associate Professor of Medicine and of the Dartmouth Institute for Health
Policy and Clinical Practice, Geisel School of Medicine at Dartmouth,
Hanover, NH
2012-present Adjunct faculty, White River Junction VA Outcomes Group
2010-2012
Assistant Professor, Dartmouth Institute for Health Policy & Clinical
Practice, Geisel School of Medicine at Dartmouth, Hanover NH
2005-2012
Assistant Professor of Medicine, Geisel School of Medicine at Dartmouth,
Hanover, NH
2004-2005
Clinical and Research Fellow in Medicine, Massachusetts General
Hospital, Harvard Medical School, Boston, MA
HOSPITAL APPOINTMENTS
2012-present Medical Director, Medical Infusion Services, Department of Medicine,
Dartmouth-Hitchcock Medical Center, Lebanon, NH
2011-present Director, Gastroenterology Research Program, Section of
Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
2005-present Director, Inflammatory Bowel Disease Center, Section of
Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
2001-present Physician, Medical Service, Department of Veterans Affairs, WRJ, VT
LICENSURE
New Hampshire, license #11395
BOARD CERTIFICATION
Gastroenterology, 2005
ABIM, 2001
USMLE Part III, 1999
USMLE Part II, 1998
USMLE Part I, 1996
PROFESSIONAL SOCIETY MEMBERSHIPS
American College of Gastroenterology
American Gastroenterological Association
Crohn’s and Colitis Foundation of America
COMMITTEES
National
Chair, Quality Improvement Task Force, National Scientific Advisory Board, Crohn’s and
Colitis Foundation of America, 2012-present
Co–Chair, National Professional Education Committee, National Scientific Advisory
Board, Crohn’s and Colitis Foundation of America, 2008 – 2011
Crohn’s and Colitis Foundation, Quality Improvement Committee, 2009-2011
Grant Review Study Section, Crohn’s and Colitis Foundation of America, 2008 – present
AGA, IBD subcommittee for Clinical Practice Planning Committee for DDW, 2010present
MKSAP Board Review Committee, Gastroenterology section
IBD Support Foundation, Medical Advisory Board
Data safety and monitoring board (DSMB) member on multiple clinical trials
Regional
Chapter Medical Advisory Committee, Crohn’s and Colitis Foundation of America, New
England Chapter, 2005-present
Institutional
Infusion Services Committee, Dartmouth-Hitchcock Medical Center, 2012-present
Clinical Trials Office, Principal Investigators’ Advisory Committee, Dartmouth-Hitchcock
Medical Center, Lebanon, NH 2011-present
Data Warehouse Committee, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 20102011
Translational Research and Education Committee, Dartmouth-Hitchcock Medical Center,
Lebanon, NH, 2008-2010
Section of Gastroenterology and Hepatology Internal Review Committee for Research
Protocols, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2006-present
Intern Selection Committee, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 20012002, 2005-present
RESEARCH GROUP/CONFERENCE ORGANIZATION
International Organization for the Study of Inflammatory Bowel Disease (IOIBD). To be
inducted March 2013. http://www.ioibd.org/
BRIDGe Group, 2007 - present. Founder of a group of 13 junior faculty IBD clinicians
and clinical researchers. Collaborative research group, further details available at
www.BRIDGeIBD.com
Dartmouth-Hitchcock/CCFA Patient Education Symposium. Chairman of annual
conferences 2006-2012.
Current and Future Treatments of Inflammatory Disorders: Common Ground for IBD,
Psoriasis and Rheumatoid Arthritis. Dartmouth-Hitchcock Medical Center, June 2007.
Steering Committee member.
JOURNAL EDITORIAL POSITIONS
Alimentary Pharmacology & Therapeutics, International Editorial Board, 2011 - present
Inflammatory Bowel Diseases, Associate Editor, 2009-present
Inflammatory Bowel Diseases, Section Editor, Selected Summaries, 2006-2009
Gastroenterology and Hepatology, Editorial Board, 2007-current
JOURNAL REVIEWER
American Journal of Gastroenterology
Alimentary Pharmacology and Therapeutics
Annals of Internal Medicine
Clinical Gastroenterology and Hepatology
Cochrane Reviews
Digestive Diseases and Sciences
Gut
Inflammatory Bowel Diseases
Gastroenterology
UpToDate
MAJOR RESARCH INTERESTS
Outcomes research in inflammatory bowel disease (IBD), risk prediction and risk
communication for patients with Crohn’s disease, quality improvement in IBD
RESEARCH SUPPORT
Past
Dartmouth-Hitchcock Medical Center, Department of Medicine Junior Faculty Research
Development Award, 2005
Dartmouth Medical School, Hitchcock Foundation: A Novel Approach to Study the
Association Between Mycobacterium Avium Complex and Crohn's Disease.
January 2001
Crohn’s and Colitis Foundation of America. Career Development Award. July 2007-June
2010. Role: PI
Foundation for Clinical Research in Inflammatory Bowel Disease. Patient knowledge
and preferences in regards to colorectal cancer in the setting of ulcerative colitis.
February 2007. Role: PI
Present
NIH K23 Career Development Award. 1K23DK078678-01A1. 2008-2013. Role: PI.
Award $797,220
Crohn’s and Colitis Foundation of America, Quality of Care Initiative. January 2011-Dec
2011. Role: Co-PI with Dr. Thomas Ullman and Dr. Gil Melmed. Award $180,000
Foundation for Clinical Research in IBD. Pilot Study of Hyperbaric Oxygen for Ulcerative
Colitis. July 2012. Role: Co-investigator. Award $40,000.
R01. 1R01HS021747-01. Evaluating a prediction tool and decision aid for patients with
Crohn’s disease. September 2012-August 2017. Role: PI. Award $2,278,000.
Under Review
Implementation strategies for a risk prediction tool for patients with Crohn’s disease –
PCORI Pilot Projects Grant – submission July 2012
AWARDS
Dartmouth-Hitchcock Department of Medicine Excellence in Teaching Award, 2009
Crohn’s and Colitis Foundation of America (CCFA) Young IBD Investigator Award, May
2008. San Diego, CA.
Research Excellence in GI and Liver (REGAL) Award recipient, October 2006,
Chicago, IL
INVITED PRESENTATIONS
Regional
“Shared Decision Making in IBD”, Medical Grand Rounds, Androscogin Valley Hospital,
Androscogin NH, May 2012
The times they are a-changin’ - Crohn’s diagnosis & treatment in 2011, Medical Grand
Rounds, Valley Regional Hospital, Claremont, NH, January 2011
Communicating the benefits and risks of Crohn’s disease therapy to patients. Combined
Medical and Pediatric Grand Rounds, Maine Medical Center, March 2011
“The times they are a-changin’ – Crohn’s diagnosis and treatment in 2009. Medical
Grand Rounds, Dartmouth-Hitchcock Medical Center, Lebanon, NH, April 2009.
“Choosing the right medications for you.” Crohn’s and Colitis Foundation of America,
New England Chapter Patient Education Symposium, Lebanon, NH, May 2008.
“Inflammatory Bowel Disease 101.” Anthem, Blue-Cross/Blue-Shield. Manchester, NH,
June 2008.
“Inflammatory Bowel Disease: Diagnosis and Treatment 2008” Medical Grand Rounds,
Lakes Region General Hospital, Laconia, NH, April 2008.
“Inflammatory Bowel Disease: Diagnosis and Treatment 2008” Boston University
Northeast Regional Nurse Practitioner Conference. April 2008.
“Understanding Your Choices about Current Treatment and Looking Towards the
Future” Crohn’s and Colitis Foundation of America, New England Chapter, Baystate
Medical Center Patient Education Symposium. October 2007.
“Making and Evaluating Choices about IBD Medications” Crohn’s and Colitis Foundation
of America, New England Chapter Patient Education Symposium, Burlington, MA, March
2008.
“Infections in IBD” Crohn’s and Colitis Foundation of America, National Research
Conference. Aventura, FL, December 2007.
“Side-Effects of IBD Medications: Putting Risk Into Perspective.” Crohn’s and Colitis
Foundation of America, New England Chapter Patient Education Symposium, Lebanon,
NH, May 2007.
“New Discoveries and the Future of IBD Treatment.” Crohn’s and Colitis Foundation of
America, New England Chapter Patient Education Symposium, Lebanon, NH, May
2007.
“State of the Art of IBD in 2007.” Key note lecture at the Maine Gastroenterology Society
Meeting, Freeport, ME, April 2007.
“Risks of IBD Medications: Should we be concerned?” Crohn’s and Colitis Foundation of
America, New England Chapter Patient Education Symposium, Burlington, MA, March
2007.
“Hot Topics in Inflammatory Bowel Disease.” Medical Grand Rounds, New London
Hospital, New London, NH, October 2006.
“Hot Topics in Inflammatory Bowel Disease.” Medical Grand Rounds, Catholic Medical
Center, Manchester, NH, June 2006
“New Treatments for Inflammatory Bowel Disease.” Crohn’s and Colitis Foundation of
America, New England Chapter Patient and Family Education Symposium, Lebanon,
NH, June 2006
“Weighing the Risks and Benefits of Therapy for IBD.” Crohn’s and Colitis Foundation of
America, New England Chapter Patient and Family Education Symposium, Lebanon,
NH, June 2006
“Hot Topics in Inflammatory Bowel Disease.” Medical Grand Rounds, Mt. Ascutney
Hospital, Windsor, VT, May 2006.
“Hot Topics in Inflammatory Bowel Disease.” Medical Grand Rounds, Manodnock
Community Hospital, Peterborough, NH, April 2006.
“Understanding the Risks and Benefits of Biologic Therapy for IBD.” Crohn’s and Colitis
Foundation Patient and Family Education Symposium. Burlington, MA, March 2006.
“Hot Topics in Inflammatory Bowel Disease.” Medical Grand Rounds, Central Vermont
Regional Hospital, Berlin, VT, March 2006.
“Update in the Treatment of IBD.” Medical Grand Rounds, Rutland Regional Hospital,
Rutland, VT, February 2006.
“Inflammatory Bowel Disease: Easy Questions, Difficult Answers.” Dartmouth-Hitchcock
Medical Center, December 2005.
“Anorectal disorders.” Gastroenterology in Primary Care. Woodstock, VT, Febuary 2004
“Crohn’s Disease.” Gastroenterology in Primary Care. Bedford, NH, June 2003
National
“Balancing the benefits and risks of IBD therapy” Crohn’s and Colitis Foundation of
America, Physician Education Program, Memphis, Tennessee, August 2012
“Risk of IBD Therapy” Digestive Disease Week, Postgraduate Course, San Diego,
California. May 2012
“Improving Quality of Care for Patients” Internal Medicine Update, Keynote Speaker,
Boca Raton Regional Hospital, Boca Raton, Florida, March 2012
“Communicating the risks and benefits of IBD therapy to our patients”. Mt. Sinai School
of Medicine, GI Grand Rounds, New York, New York. February 2012
“Do IBD therapies cause cancer?” Crohn’s and Colitis Foundation of America National
Research Conference, Hollywood, FL, December 2011.
“Optimizing biologic therapy” Crohn’s and Colitis Foundation of America National
Research Conference, Hollywood, FL, December 2011.
“Communicating with the IBD patient: How to convey benefits and risks” American
College of Gastroenterology Postgraduate Course, National Harbor, Maryland, October
2011
“Cochrane symposium – evidence based algorithm for the treatment of ulcerative colitis,”
Digestive Disease Week, Chicago, IL, May 2011
“When is it time to start anti-TNF therapy,” Digestive Disease Week, Chicago, IL, May
2011
“Meet the professor – management of Crohn’s disease,” Digestive Disease Week,
Chicago, IL, May 2011
“Quality of care in IBD,” Digestive Disease Week, Canadian trainee program,
Chicago, IL, May 2011
“Communicating the Risks and Benefits of Crohn’s Disease Therapy to our Patients,”
GI Grand Rounds, Rhode Island Hospital, Providence, RI, February 2011
“From inception to implementation: Development of the Crohn’s Disease Risk Prediction
Model”, GI Research Conference, Rhode Island Hospital, Providence, RI, February 2011
“Communicating the Risks and Benefits of Crohn’s Disease Therapy to our Patients,”
GI Grand Rounds, Beth Israel Medical Center, New York, New York, February 2011
“Communicating the Risks and Benefits of Crohn’s Disease Therapy to our Patients,”
Case University Hospitals, Cleveland, OH, January 2011
“Communicating the Risks and Benefits of Crohn’s Disease Therapy to our Patients,”
University of Miami, Miami, FL, January 2011
“Quality of care in IBD”, Crohn’s and Colitis Foundation of America National
Research Conference, Hollywood, FL, December 2010.
“IBD patients who never had IBD”, Crohn’s and Colitis Foundation of America
National Research Conference, Hollywood, FL, December 2010.
“Communicating Risk of Inflammatory Bowel Disease Therapy,” Scripps Annual IBD
Symposium, La Jolla, September 2010
“Dealing with the risks of IBD therapy,” Digestive Disease Week, Postgraduate Course,
New Orleans, LA, May 2010
“Cancer in IBD Therapy,” Digestive Disease Week, Clinical Symposium, New Orleans,
LA, May 2010
“Communicating Risks and Benefits of IBD Therapy,” NYU Annual GI Update, New York,
NY, April 2010
“Communicating the Risks of IBD Therapy to Patients and their Parents,” Childrens’
Hospital, Boston, MA, April 2010
“Communicating risks of IBD therapies to patients and their parents” Crohn’s and Colitis
Foundation of American National Research Conference, Hollywood, FL, December
2009.
“Introduction to Quality Improvement in IBD” Crohn’s and Colitis Foundation of American
National Research Conference, Hollywood, FL, December 2009.
“Risk and Risk Communication in IBD” Cleveland Clinic, Annual George Rankin Lecture,
Cleveland, OH, November 2009
“How to discuss risks of IBD therapies with your patients without scaring them” Mt. Sinai
School of Medicine IBD Symposium. New York, NY. September 2009.
“Risks and Benefits of IBD Treatments” University of North Carolina IBD Day. Chapel
Hill, NC. September 2009.
“IBD Update” CCFA Physicians’ Dinner. Minneapolis, MN. June 2009.
“Prevention of Infectious in IBD” Boston IBD Symposium, Boston, MA, April 2009
“When and How to Use Biologic Therapy for the Treatment of IBD” ACG Regional
Meeting, Las Vegas, NV, March 2009
“Personalized Treatment for Patients with Crohn’s Disease” Walter Reed/ACG GI
Symposium, Tysons Corner, VA, March 2009
“Communicating Risks and Benefits to IBD Patients” Crohn’s and Colitis Foundation of
American National Research Conference, Hollywood, FL, December 2008.
“Diagnosis, Treatment and Prevention of Infectious Complications of IBD” Crohn’s and
Colitis Foundation of American National Research Conference, Hollywood, FL,
December 2008.
“Infections in IBD” Massachusetts General Hospital Annual IBD Course, Boston, MA
October 2008.
“Are biologic safe?” American College of Gastroenterology Annual Meeting, Orlando,
Florida, October 2008.
“Risks and Benefits of the Treatment of Crohn’s Disease.” Cedars-Sinai Medical Center
Annual Update. Lake Tahoe, CA, September 2008.
“Risks in Crohn’s disease: Balancing the risks of the disease against the risks of the
drugs” AGA forum, Digestive Disease Week, San Diego, CA, May 2008.
“Microscopic colitis” Meet-the-professor, Digestive Disease Week, San Diego, CA, May
2008.
“Balancing the Risks and Benefits of IBD Therapy: What Should we Tell our Patients?”
Visiting Professor, Yale University Section of Gastroenterology. New Haven, CT. April
2008.
“Short and Long Term Risk of IBD therapy” 3rd Biannual Clinical Advances in
Gastroenterology and Hepatology (Jefferson Medical College). San Juan, Puerto Rico,
March 2008.
“Balancing Efficacy and Risk: What do we tell our patients?” American College of
Gastroenterology, Symposium Talk, Philadelphia, PA. October 2007.
“Risk and Risk Communication for the Treatment of IBD.” Visiting Professor, University
of Michigan, Ann Arbor, MI, September 2007.
“Meet-the-Professor, Microscopic Colitis.” Digestive Disease Week, Washington, DC,
May 2007.
“How to weigh the risks and benefits of treatment for IBD: Gaining perspective” Crohn’s
and Colitis Foundation of America, Los Angeles Chapter Patient Education Program,
Los Angeles, CA, March 2007.
“Safety of Immunomodulation in IBD: What is the evidence and what should we tell our
patients?” Crohn’s and Colitis Foundation of America, Los Angeles Chapter Physician
Education Program. Los Angeles, CA, March 2007.
“Side Effects of IBD Medications: How and what do we tell our patients?” Crohn’s and
Colitis Foundation of America, National Research Conference. Miami, FL, December
2006.
“Safety of Biologic Therapy: What is the Evidence?” Physician Symposium, North
American Society for Pediatric Gastroenterology, Hepatology and Nutrition
(NASPGHAN). Orlando, FL, October 2006.
“Risk and Risk Communication in the Treatment of Inflammatory Bowel Disease.”
Mayo Clinic, Rochester, MN, October 2006.
“Risk and Benefits of Infliximab in the Treatment of Crohn’s Disease.” REGAL awards,
Chicago, IL, October 2006.
“Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease.” Digestive
Disease Week, Oral Presentation, Los Angeles, CA, May 2006
“Crohn’s Colitis and Colorectal Cancer.” Digestive Disease Week, Oral Presentation, Los
Angeles, CA, May 2006
“How to Get Started in an Academic IBD Career.” American Gastroenterological
Association Investing in the Future Program, Los Angeles, CA, May 2006
“Discussing Risks of Treatment with Patients: A Review of Common Medications and
Major Side Effects.” Crohn’s and Colitis Foundation Medical Symposium, Chicago, IL,
February 2006.
“New Biologics: The Choices and the Risks.” Crohn’s and Colitis Foundation Medical
Symposium, Chicago, IL, February 2006.
“Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease.” Crohn’s and
Colitis Foundation National Research Conference, Miami, FL, December 2005.
“Difficult IBD Cases.” Dartmouth-Hitchcock Update in Gastroenterology and Hepatology,
Manchester, NH, May 2005.
“Risk/Benefit Analysis of Infliximab in Crohn’s Disease.” Massachusetts General Hospital
Research Retreat, Boston, MA, January 2005.
International
Canterbury Bowel & Liver Trust Visiting IBD Professor
“Communicating the risks and benefits of therapy to IBD patients”, Annual Immune
Mediated Inflammatory Disease Conference, Nelson, New Zealand, September 2012
Canterbury Bowel & Liver Trust Visiting IBD Professor
“Personalized Medicine for Inflammatory Bowel Disease Patients”, Annual Immune
Mediated Inflammatory Disease Conference, Nelson, New Zealand, September 2012
“Communicating the risks and benefits of therapy to patients with Crohn’s disease”
University of Western Ontario. GI Grand Rounds. London, Ontario, April 2012
“Do IBD therapies cause cancer,” United European Gastroenterology Week (UEGW),
Stockholm, Sweden, October 2011
“Explaining the risk of IBD therapy to our patients,” Austrian National IBD Meeting
(ÖGGH), Mondsee, Austria, September 2011
“Does every patient with Crohn’s disease need immunomodulator and/or anti-TNF
therapy?” Austrian National IBD Meeting (ÖGGH), Mondsee, Austria, September 2011
“Safety of anti-TNF therapy and effective risk communication to patients,” Greek IBD
Society National Meeding, Kalamata, Greece, May 2011
“Can long-term outcomes be predicted,” St. Vincent’s Hospital IBD Symposium,
Melbourne, Australia, April 2011
“The risk versus benefit of combination therapy,” St. Vincent’s Hospital IBD Symposium,
Melbourne, Australia, April 2011
“Is colonoscopic surveillance necessary in Crohn’s disease?” St. Vincent’s Hospital IBD
Symposium, Melbourne, Australia, April 2011
“Modeling outcomes in Crohn’s disease?” St. Vincent’s Inaugural Paediatric IBD
Symposium, Melbourne, Australia, April 2011
“Benefit/Risk of treatments in IBD: the patients’ perspective,” SNFGE-AGA Cosponsored IBD Symposium, Paris, France, March 2011
“Detection and prevention of dysplasia in ulcerative colitis,” SNFGE-AGA Cosponsored IBD Symposium, Paris, France, March 2011
“Extraintestinal Cancer in IBD,” European Crohn’s and Colitis Organization Annual
Meeting, Dublin, Ireland, February 2011
“Communicating the Risks and Benefits of Crohn’s Disease Therapy to our Patients,”
GI Grand Rounds, Hospital for Sick Kids, Toronto, ON, Canada, November 2010
“Communicating the Risks and Benefits of Crohn’s Disease Therapy to our Patients,”
GI Grand Rounds, McMaster University, November 2010
“Lymphoma Risk of Inflammatory Bowel Disease Therapy,” IBD Ahead Symposium,
Brussels, Belgium, September 2010
“Exercising patient choice: Communicating Benefits and Risks of IBD Therapy,” British
Society of Gastroenterology, Liverpool, UK, March 2010
“Risk and Risk Communication in IBD”, University of British Columbia, Vancouver, BC,
Canada, January 2010
“When to use early anti-TNF therapy for Crohn’s disease”, University of Calgary, Alberta,
Canada, January 2010
“Communicating risks of IBD therapies” United European Gastroenterology Week,
London, UK, November 2009
“Balancing Risks and Benefits of IBD Therapy” IBD Ahead Symposium, St. Julians,
Malta, April 2009
“Risk and Risk Communication in IBD” GI Grand Rounds, University of Manitoba,
Winnipeg, Manitoba, October 2008.
“Risk Assessment with IBD Therapeutics: What do we know and what should we tell our
patients?” Western Canada IBD Symposium, Banff, Albert, CA. November 2007.
BIBLIOGRAPHY
Original Publications
Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J,
Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA.
Setting priorities for comparative effectiveness research in inflammatory bowel disease:
Results of an international provider survey, expert RAND panel, and patient focus
groups. Inflamm Bowel Dis 2012; Epub ahead of print.
Ha C. Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized clinical trials
do not represent the inflammation bowel disease patient population. Clin Gastroenterol
Hepatol 2012; Epub ahead of print
Lacy BE, Everhart KK, Weiser KT, Delee R, Strobel S, Siegel C, Croweel MD. IBS
patients’ willingness to take risks with medications. Am J Gastroenterol 2012;107(6):804809.
Siegel CA, Finlayson SR, Sands BE, Tosteson AN. Adverse events do not outweigh
benefits of combination therapy for Crohn’s disease in a decision analytic model. Clin
Gastroenterol Hepatol. 2012;10(1):46-51. PMID 21963958
Ashworth LA, Billett A, Mitchell P, Nuti F, Siegel C, Bosvaros A. Lymphoma risk in
children and young adults with inflammatory bowel disease; Analysis of a large singlecenter cohort. Inflamm Bowel Dis 2012;18(5):838-43.
Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA,
Sandborn WJ, Travis SP, Colombel JF. The London position statement of the world
congress of gastroenterology on biological therapy for IBD with the European Crohn’s
and Colitis Organization: Safety. Am J Gastroenterol 2011;106(9):1594-602
D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer
SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A,
Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C,
Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. The London
Position Statement of the World Congress of Gastroenterology on Biological Therapy for
IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop,
Which Drug to Choose, and How to Predict Response? Am J Gastroenterol,
2011;106:199-212.
Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N,
Mack DR, Crandall W, Evans J, Keljo DJ, Otley AR, Oliva-Hemker M, Farrior S, Langton
CR, Wrobel IT, Wahbeh G, Quiros JA, Silber G, Bahar RJ, Sands BE, Dubinsky MC. A
Real-time tool to display the predicted disease course and treatment response for
children with Crohn's disease. Inflamm Bowel Dis 2011; 17:30-8.
Johnson FR, Hauber B, Ozdemir S, Siegel CA, Hass S, Sands BE. Are
gastroenterologists less tolerant of treatment risks than patients? Benefit risk
preferences in Crohn’s disease management. J Manag Care Pharm. 2010;16:616.
Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM,
Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. The
appropriateness of concomitant immunonomodulators and anti-TNF agents for Crohn’s
disease: One size does not fit all. Clin Gastroenterol Hepatol 2010; 8:655.
Baars JE, Siegel CA, Van’t Spijker A, Markus T, Kuipers EJ, van der Woude CJ.
Inflammatory bowel disease patients are insufficiently educated about the basic
characteristics of their disease and the associated risk of colorectal cancer. Dig Liver Dis
2010; Epub ahead of print
Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE.
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch
between patient preferences and physician recommendations. Inflamm Bowel Dis
2010;16:1658-62.
Rubin DT, Dubinksy MC, Panaccione R, Siegel CA, Binion DG, Kane SV, Hopper J.
The impact of ulcerative colitis on patients’ lives compared to other chronic diseases: A
patient survey. Dig Dis Sci. 2010; 55:1044.
Wilcox AR, Dragnev C, Darcey CJ, Siegel CA. A new tool to measure the burden of
Crohn’s disease and its treatment: Do patient and physician perceptions match? Inflamm
Bowel Dis 2010;16:645.
Awais D, Siegel CA, Higgins PD. Modeling dysplasia detection in ulcerative colitis:
Clinical implications of surveillance intensity. Gut 2009;58:1498.
Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of Lymphoma
Associated with Combination Anti-TNF and Immunomodulator Therapy for the
Treatment of Crohn’s Disease: A Meta-Analysis. Clinical Gastroenterology and
Hepatology 2009;7:874. *NOTE – this manuscript was in the “Top 10” most cited
manuscripts in this journal from 2008-2010.
Courville EL, Siegel CA, Vay T, Wilcox AR, Suriawinata AA, Srivastava A. Isolated
Asymptomatic Ileitis Does Not Progress To Overt Crohn's Disease On Long Term Follow
Up Despite Features Of Chronicity In Ileal Biopsies. Am J Surg Pathol 2009;33:1341.
Baars JE, Siegel CA, Kuipers EJ, van der Woude CJ. Patient’s perspectives important
for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion
2009;79:30-35.
Rubin DT, Siegel CA, Kane SV, Binion DG, Panaccione R, Dubinsky MC, Loftus EV,
Hopper J. Impact of ulcerative colitis from patients’ and physicians’ perspectives: Results
from the UC: NORMAL survey. Inflamm Bowel Dis. 2009 Apr;15(4):581-8..
Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE. Are adult patients
more tolerant of treatment risks than parents of juvenile patients? Risk Analysis
2009;29(1):121-136.
Spiegel BM, Ho W, Esrailian E, Targan S, Higgins P, Siegel CA, Dubinsky M, Melmed G.
Controversies in ulcerative colitis: A survey comparing decision making of experts
versus community gastroenterologists. Clin Gastroenterol Hepatol 2008;7(2):169-74.
Siegel CA, Levy LC, Mackenzie, Sands BE. Patient perceptions of the risks and benefits
of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis
2008;14(1): 1-6.
Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands, BE.
Crohn's Disease Patients' Benefit-Risk Preferences: Serious Adverse Event Risks
versus Treatment Efficacy. Gastroenterology 2007;133(3):769-79.
Siegel CA, Hur C, Korzenik JR, Gazelle, GS, Sands BE. Risks and benefits of infliximab
for the treatment of Crohn’s disease. Clinical Gastroenterology and Hepatology
2006;4:1017-1024.
Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn’s colitis: A case-control
study. Inflammatory Bowel Diseases 2006;12:491-496.
Reddy D, Siegel CA, Sands BE, Kane S. Possible association between isotretinoin and
inflammatory bowel disease. Am Journal Gastroenterol 2006;101:1569-1573.
Review articles
Devlin SM, Cheifetz AS, Siegel CA, on behalf of the BRIDGe Group. Patient-specific
approach to combination versus monotherapy with the use of antitumor necrosis factor α
agents for inflammatory bowel disease. Gastroenterol Clin North Am 2012;41(2):411.28.
Feuerstein JD, Cheifetz AS, Siegel CA. Comparative effectiveness research in
inflammatory bowel disease: prospects and challenges. Expert Rev Gastroenterol
Hepatol 2012;6:405-407.
Levy LC, Siegel CA. Commentary: diagnostic medical radiation exposure in
inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(8):959-60.
Siegel CA. Shared decision making in inflammatory bowel disease: helping patients
understand the tradeoffs between treatment options. Gut 2012;61(3):459-65.
Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to
patients. Aliment Pharmacol Ther. 2011;33:23-32.
Levy LC, Siegel CA. Endoscopic mucosal healing in ulcerative colitis. Aliment Pharmacol
Ther. 2011;33:1254-5.
Loew BJ, Siegel CA. Foam preparations for the treatment of ulcerative colitis. Current
Drug Delivery 2011. Epub ahead of print.
Siegel CA. What options do we have for induction therapy for Crohn’s disease.
Digestive Diseases 2010;28:543-7.
Siegel CA. Should mucosal healing be a primary endpoint in clinical trials of Crohn’s
disease? Pro. AGA Perspectives, Oct/Nov 2010.
Siegel CA. Lost in translation: Helping patients understand the risks of inflammatory
bowel disease therapy. Inflamm Bowel Dis 2010;16:2168.
Siegel CA. Creating quality measures in IBD. Gastroenterology & Hepatology
2010;6:218.
Siegel CA. Accidentally ASCENDing into comparative effectiveness research for
inflammatory bowel disease; Gastroenterology 2009;137:1880.
Siegel CA. Risk of lymphoma in inflammatory bowel disease. Gastroenterology and
Hepatology 2009;5(11):1.
Siegel CA, Marden S, Sands BE. Response to: Insufficient evidence to conclude
whether anti-TNF therapy increases the risk of lymphoma in Crohn’s disease. Clin
Gastroenterol and Hepatol 2009;7:1139.
Siegel CA, Melmed GY, Ullman TA. Quality of care in inflammatory bowel disease: A
STEEEP challenge. Inlamm Bowel Dis. 2009;16:134.
Johnson FR, Hauber AB, Ozdemir S, Hass S, Siegel C, Sands B. Quantitative benefitrisk tradeoff preferences for Crohn’s disease treatments - Implications for regulatory
decision making and disease management. Int J Med Biol Front 2009;15(5/6):457-466
Siegel CA, Melmed GY. Review: Predicting response to anti-TNF agents for the
treatment of Crohn’s disease. Therapeutic Advances in Gastroenterology 2009; 2:245.
Siegel CA. Making therapeutic decisions in IBD: The role of patients. Current Opinion in
Gastroenterology 2009;25:334.
Siegel CA, Macdermott RP. Is chronic pain an extraintestinal manifestation of IBD?
Inflamm Bowel Dis. 2009; 15:769.
Marden SM, Siegel CA. Give me prednisone and give me death. Inflamm Bowel Dis.
2009; 15:1119.
Sparrow MP, Irving PM, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Jones
J, Kozuch PL, Melmed GY, Velayos FS, Siegel CA. Current controversies in Crohn’s
disease: A roundtable discussion of the BRIDGe group. Gastroenterology & Hepatology
2008; 4(10):713-720.
Siegel CA. Communicating the risks of inflammatory bowel disease medications to
patients. Inflamm Bowel Dis Monit;2008(3):78-83.
Siegel CA. Patient perspectives on therapeutic options for IBD. Gastroenterology and
Hepatology 2007; 3(12):909-911.
Hanauer SB, Kane SV, Plevy SE, Siegel CA. A case-based discussion of managing
Crohn’s disease: Integrating the new generation of anti-TNF therapies.
Gastroenterology and Hepatology 2007; 3(12):3-14.
Siegel CA. Guide to discussing the risks of immunomodulator and anti-TNF therapy with
inflammatory bowel disease patients. Practical Gastroenterology 2007; XXXI (11): 1424.
Siegel CA. Embracing the internet for progress in shared decision making. Inflamm
Bowel Dis 2007;13(12):1579-1580.
Levy LC, Siegel CA. Adherence issues in the treatment of ulcerative colitis. Medscape
Internal Medicine. Available at: http://www.medscape.com/viewarticle/563408
Siegel CA, Rubin DT. American College of Gastroenterology Annual Scientific Meeting
2006 Review. Inflammatory Bowel Disease Monitor 2007;7(3):121-124.
Siegel CA, Bensen, S, Ely P. Should rare complications of treatment influence decisionmaking in ulcerative colitis? Inflammatory Bowel Diseases 2007;13:242.
Siegel, CA. Safe and Effective Use of Immunomodulators for Inflammatory Bowel
Disease. Practical Gastroenterology 2006;7:31-44.
Siegel, CA. As if mothers don’t have enough to worry about…Inflamm Bowel Dis.
2006;12(2):146-147.
Siegel CA, Sands BE. Review article: practical management of inflammatory bowel
disease patients taking immunomodulators. Alimentary Pharmacology & Therapeutics
2005;22 (1):1-16.
Siegel CA, Silas AE, Suriawinata AA, van Leeuwen DJ. Liver Biopsy 2005: When and
How? Cleveland Clinic Journal of Medicine 2005;72(3):199-224.
Siegel CA. Take two prednisone and don’t call me in the morning. Inflamm Bowel Dis.
2005;11(2):206-7.
Siegel CA, Book Review of Gastrointestinal Symptoms in Advanced Cancer Patients.
Journal of Palliative Care 2004;7:89.
Siegel CA, Robertson DJ. Print and Media Review of Gastroenterology and Hepatology
for the Primary Care Provider: Principles, Practice and Guidelines for Referral.
Gastroenterology 2003;124:1160-1161.
Book Editor
Irving PM, Siegel CA, Rampton DS, Shanahan F, eds. Inflammatory Bowel Disease:
New Challenges (second edition). 2011. Oxford: Wiley-Blackwell
Book Chapters
Siegel CA (2011). Balancing benefits and risks of biologic therapy. In: Bayless TM,
Hanauer SB, eds. Advanced Therapy in Inflammatory Bowel Disease. (pp. 723-728).
Shelton, Connecticut: People’s Medical Publishing House.
Siegel CA (2011). The risks of immunomodulators and biologics: what should we tell
patients? In: Irving PM, Siegel CA, Rampton DS, Shanahan F, eds. Inflammatory Bowel
Disease: New Challenges. (pp. 140-143). Oxford: Wiley-Blackwell
Korzenik JR, Siegel,CA (2011). The limitations of applying evidence based medicine to
inflammatory bowel disease: what we do not learn from clinical trials. In: Lichtenstein G,
ed. Ulcerative Colitis: The complete guide to medical management. (pp. 71-78).
Thorofare: Slack incorporated.
Korzenik JR, Siegel,CA (2011). The limitations of applying evidence based medicine to
inflammatory bowel disease: what we do not learn from clinical trials. In: Lichtenstein G,
ed. Crohn’s disease: The complete guide to medical management. (pp. 69-76).
Thorofare: Slack incorporated.
Levy LC, Siegel CA (2011). State of the art medical treatment for the adult patient with
IBD: The mesalamine based therapies. In: Cohen R, ed. Inflammatory bowel disease
diagnosis and therapeutics – 2nd edition (pp. 59-71). New York: Humana Press.
Sands BE, Siegel CA (2010). Crohn’s Disease. In: M Feldman, LS Friedman, LJ Brandt,
eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 9th edition (pp.1941
-1973). Philadelphia: Saunders/Elsevier.
Siegel CA (2010). Comprehensive approach to patient risk. Risk versus benefit of
biologics and immune suppressants. In: SR Targan, F Shanahan, LC Karp, eds.
Inflammatory bowel disease: Translating basic science into clinical practice (pp. 678692). Oxford, UK: Wiley-Blackwell.
Siegel CA (2010). Risks and complications of biologic therapy. In: D Baumgart, ed.
Biologic therapy for inflammatory bowel disease (pp. 64-73). Bremen: UNI-MED.
Siegel CA, Sands BE (2010). The first visit. In: SJ Bickston, RS Bloomfeld, eds.
Handbook of inflammatory bowel disease (pp. 1-8). Baltimore: Wolters Kluwer/Lippincott
Williams and Wilkins.
Siegel CA (2010). The risks of biologic therapy for inflammatory bowel disease. In: CN
Bernstein, ed. The inflammatory bowel disease yearbook, volume 6 (pp.89-108).
London, UK: Remedica.
Levy LC, Siegel CA (2009). What are the risks of biologic therapies and how do you
communicate this to patients? In: DT Rubin, FA Farraye, S Friedman, eds. Curbside
Consultations in Gastroenterology (pp. 27-32). Thorofare: Slack incorporated.
Siegel CA (2009). Inflammatory bowel disease in the current world: Controversies in
Management. In: MC Dubinsky, EJ Scherl, eds. The life cycle and IBD: A focus on
special populations (pp. 231-244). Thorofare: Slack incorporated.
Johnson FR, Hauber AB, Ozdemir S, Hass S. Siegel CA, Sands BE. Quantitative
benefit-risk tradeoff preference for Crohn’s disease treatments – Implications for
regulatory decision making and disease management. In: Crohn’s disease: Etiology,
Pathogenesis and Interventions. In press.
Siegel CA, Levy, LC. What tips should I give my surgical colleagues who are seeing
patients with pouchitis? In: Cash B, ed. Curbside consultation of the colon: 49 clinical
questions. In press.
Abstracts
Corey A. Siegel, Phillip Fleshner, Lori S. Siegel, Jerome Rotter, Marla Dubinsky, Eric
Vasilauskas, Andy Ippoliti, David Shih, Gil Melmed, Carol Landers, Talin Haritunians,
Stephan Targan, Kent Taylor, Dermot McGovern. Predicting Crohn’s disease postoperative recurrence using clinical, endoscopic, serologic and genetic factors. Digestive
Disease Week, Chicago, IL, May 10, 2011
Corey A. Siegel, Sadie M. Marden, Lori S. Siegel, Marla C. Dubinsky, Annette M.
O’Connor. Development of the first Crohn’s disease decision aid:
helping patients make informed, preference-based decisions for their treatment.
Digestive Disease Week, Chicago, IL, May 10, 2011
Lori Ann Ashworth, Amy Billett, Paul Mitchell, Federica Nut, Corey Siegel, Athos
Bousvaros. Lymphoma risk in children and young adults with inflammatory bowel
disease: analysis of a large single center cohort. Digestive Disease Week, Chicago, IL,
May 9, 2011
Corey Siegel, Sadie Marden, Courtney Kozlowski, Burr Loew, Campbell Levy, Steve
Bensen. Crohn’s disease patients report their definitions of “rare” adverse events,
remission and the importance of mucosal healing: what patients REALLY think.
Digestive Disease Week, Chicago, IL, May 9, 2011
Christina Ha, Thomas Ullman, Corey A. Siegel, Asher Kornbluth. Are patients enrolled in
randomized controlled trials (RCTs) representative of the general Inflammatory Bowel
Disease (IBD) patient population? Digestive Disease Week, Chicago, IL, May 9, 2011
Anderson P, King L, Landers C, McGovern D, Kane E, Taylor K, Melmed G, Kelly V,
Wilcox A, Srivastava A, Siegel CA. Serologic and genetic profiles of patients with
incidental asymptomatic ileitis. Digestive Disease Week, New Orleans, LA. May 4,
2010.
White LC, Spangler C, Rosenblum J, Sweeney S, Homan E, Bensen S, Levy LC,
Dragnev MC, Moskalenko-Locke K, Siegel CA. A quality improvement project
significantly increased the vaccination rate for immune suppressed IBD patients.
Digestive Disease Week, New Orleans, LA. May 4, 2010.
Siegel CA, Finalyson SR, Sands BE, Tosteson. AN. A decision analysis to define the
thresholds at which the risks of combination azathioprine and infliximab therapy
outweigh its benefits. American College of Gastroenterology , San Diego, CA, Oct 27,
2009.
Siegel CA, Sands BE, Feagan B, Sandborn WJ, Hass S, Niecko T. Natalizumab reduces
the rate of hospitalization in moderate to severe Crohn’s patients: Data from the ENACT
and ENCORE Trials. American College of Gastroenterology, San Diego, CA, Oct 27,
2009.
Melmed G, Spiegel B, Bressler B, Cheifetz A, Devlin S, Harrell L, Irving P, Jones J,
Kaplan G, Kozuch P, Velayos F, Baidoo L, Sparrow M, Siegel, C. When is it appropriate
to use concomitant immunomodulators with anti-TNF agents for the treatment of
Crohn’s disease? Results of a RAND appropriateness panel. American College of
Gastroenterology, San Diego, CA, Oct 26, 2009 – Presidential Poster Award
Lacy, BE, Everhart KK, Weiser KW, De Lee R, Strobel, S, Siegel CA, Cowell, MD.
Medication Risk Taking Behavior in IBS Patients. American College of
Gastroenterology, San Diego, CA, October 25, 2009, Presidential Poster Award
Siegel CA, Siegel LS, Hyams J, Kugathasan S, Markowitz J, Rosh J, Leleiko N, Mack D,
Crandall W, Evans J, Keljo D, Otley A, Oliva-Hemker M, Langton C, Wrobel IT,
Wahbeh G, Quiros A, Silber G, Bahar R, Sands BE, Dubinsky MC. A Prediction Tool to
Help Children with Crohn's Disease and their Parents Understand Individualized Risks
of Disease Complications and Response to Therapy. Digestive Disease Week, Chicago,
IL. June 3, 2009.
Sweeney S, King A, Bihrle M, Ortego A, Siegel CA. Do Barriers to Access of
Care Impact Outcomes in Patients with Crohn’s Disease? Digestive Disease Week,
Chicago, IL. May 31, 2009.
Mahadevan U, Siegel CA, Abreu M. Certolizumab use in pregnancy: Low levels detected
in cord blood. Digestive Disease Week, Chicago, IL. June 3, 2009.
Kreuter JD, Siegel CA, Gardner TB, Srivastava A, Suriawinata AA. Density of IgG4+
Plasma Cells in Ulcerative Colitis Correlates with the Degree of Inflammation and not
with Extraintestinal Manifestations. United States and Canadian Academy of Pathology,
Boston, MA, March 2009.
Wilcox AR, Dragnev C, Darcey CJ, Siegel CA. A new tool to measure the burden of
Crohn’s disease and its treatment: Do patient and physician perceptions match? Am
Journal Gastroenerol 2008.103(S1):S425.
Siegel CA, Siegel LS, Sands BE, Wrobel I, Wahbeh G, Quiros A, Silber G, Bahar R,
Dubinsky MC. A prototype system dynamics model to communicate the risk of Crohn’s
disease complications to patients and their predicted treatment response. Am Journal
Gastroenerol 2008.103(S1):S451.
Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma
associated with anti-TNF agents for the treatment of Crohn’s disease: A meta-analysis.
Gastroenterology 2008;134(4):A14.
Awais D, Litt AK, Siegel CA, Higgins P. Modeling dysplasia detection in ulcerative colitis:
clinical implications of surveillance sensitivity. Gastroenterology 2008;134(4):A34.
Sands BE, Siegel CA, Spencer M, Hass S. Natalizumab reduces the hospitalization rate
in moderate to severe Crohn’s disease patients: A pooled analysis of the ENACT-1 and
ENCORE studies. Gastroenterology 2008;134(4):A154.
Baars JE, Siegel CA, van’t Spijker A, Kuipers EJ, van der Woude CJ. Patients with
inflammatory bowel disease are insufficiently educated about their disease and
associated risks. Gastroenterology 2008;134(4):A200.
Spiegel BM, Ho W, Esrailian E, Melmed GY, Higgins PD, Siegel CA, Dubinsky MC,
Targan SR. Practice patterns of 5-ASA use in ulcerative colitis (UC): Results of a
national vignette survey comparing experts vs. community providers. Gastroenterology
2008;134(4):A209.
Spiegel BM, Ho W, Esrailian E, Melmed GY, Higgins PD, Siegel CA, Dubinsky MC,
Targan SR. Experts and community providers have varying levels of beliefs about the
appropriateness of colectomy for flat low-grade dysplasia (LGD) in ulcerative colitis UC).
Gastroenterology 2008;134(4):A345.
Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Bunnag AP, Vay T, Baars JE,
Sands BE. When should ulcerative colitis patients undergo colectomy for dysplasia?
Mismatch between patient preferences and physician recommendations.
Gastroenterology 2008;134(4):A346.
Fingar EL, Vay T, Wilcox A, Siegel C, Suriawinata AA, Srivastava A.
Isolated Asymptomatic Ileitis Does Not Progress to Crohn s Disease Despite
Presence of Features of Chronicity in Ileal Biopsies. Modern Pathology, Vol 21 (Suppl 1;
January) 2008; 118A. Runner-up, GI Pathology Best Abstract Prize.
Baars JE, Siegel CA, van ‘t Spijker A, Kuipers EJ, van der Woude CJ. Patients with
inflammatory bowel disease are insufficiently educated about their disease and
associated risks. Presented at the European Crohn’s and Colitis Organization Congress
Lyon, France 2008.
Rubin DT, Siegel CA, Kane SV, Binion DG, Panaccione R, Dubinsky MC, Hopper J.
Patient and Physician Perceptions on Living with Ulcerative Colitis: Results from Two
Internet Surveys. American Journal of Gastroenterology 102: S310 527 Suppl. 2 SEP
2007. (Also presented as posters at Advances in IBD Miami FL 2007, CDDW 2008
Montreal Quebec Canada 2008)
Rubin DT, Dubinsky MC, Panaccione R, Siegel CA, Binion DG, Kane SV, Hopper J.
The impact of ulcerative colitis on patients’ lives compared with other chronic
diseases: a survey of patients’ opinions. American Journal of Gastroenerology 102:
S483 994 Suppl. 2 SEP 2007. (Poster presentations at Advances in IBD Miami FL
2007, BSG 2008 Birmingham UK, CDDW 2008 Montreal Quebec Canada 2008)
Sands BE, Siegel CA, Johnson R, Ozdemir S, Hass S, Miller DW. Gastroenterologists’
Tolerance for Crohn’s Disease Treatment Risks. United European Gastroenterology
Week, Paris, France, October 2007.
Siegel CA, Van der Toorn P, Levy LC, Mackenzie T, Van der Woude C. International
differences in patient perceptions of the benefits and risks of infliximab.
Gastroenterology 2007;132(4,Suppl 2):A-515.
Siegel CA, Levy LC, Mackenzie T, Sands BE. Patient perceptions of the risks and
benefits of infliximab for the treatment of Crohn’s disease. Am J Gastroenterol
2006;101:S438.
Siegel CA, Kamin I, Sands BE. Risk factors for colorectal cancer in Crohn’s colitis: A
Case control study. Gastroenterology 2006;130(4):A2.
Siegel CA, Hur C, Korzenik JR, Sands BE. Risks and benefits of infliximab for the
treatment of Crohn’s disease. Gastroenterology 2006;130(4):A71.
Sands B, Siegel C, Hass S, Miller D, White J, Johnson R, Ozdemir S. Crohn’s disease
patients’ willingness to accept the risks of serious adverse events in exchange for clinical
benefits. Gastroenterology 2006;130(4):A656.
Siegel CA, Olenec CA, Wartman DG, Bensen SP, Ely P. Hemophagocytic syndrome: A
complication of ulcerative colitis or side-effect of 6-MP therapy? The American Journal of
Gastroenterology 2004;99(10):S134.
Siegel CA, Bensen S, Marsh B, Robertson D, Wadell R, Hynes M, Kelly V, Cole B, Von
Reyn CF. Skin Testing to Evaluate the Association Between Crohn’s Disease and
Mycobacterial Infection. The American Journal of Gastroenterology 2001;97(9): S267.
Gilbert RJ, Dillon S, Yakubovich M, Siegel C, Pothoulakis C, Lamont JT, Feig LA.
Cytotoxicity Due To Clostridium Difficile Toxin B Is Associated With
Modification Of The Small Molecular Weight GTP-Binding Protein rho A.
Gastroenterology 1994. 106;A688.
Gilbert RJ, Siegel C, Yakubovich M, Dillon S, Feig L, Pothoulakis C, Lamont JT.
Clostridium Difficile Toxin B Inhibits ADP-Ribosylation Of rho A In Pancreatic
Microsomal Membranes. Gastroenterology 1993;104: A706.
Date updated: 11/27/12
By: Corey A. Siegel